Emergent BioSolutions Inc (EBS)
9.51
+0.11
(+1.17%)
USD |
NYSE |
Nov 22, 10:51
Emergent BioSolutions Enterprise Value: 1.022B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.022B |
| November 20, 2024 | 993.86M |
| November 19, 2024 | 960.80M |
| November 18, 2024 | 978.68M |
| November 15, 2024 | 931.00M |
| November 14, 2024 | 1.015B |
| November 13, 2024 | 1.053B |
| November 12, 2024 | 1.103B |
| November 11, 2024 | 1.161B |
| November 08, 2024 | 1.150B |
| November 07, 2024 | 1.109B |
| November 06, 2024 | 1.011B |
| November 05, 2024 | 998.19M |
| November 04, 2024 | 987.90M |
| November 01, 2024 | 1.007B |
| October 31, 2024 | 1.004B |
| October 30, 2024 | 1.033B |
| October 29, 2024 | 1.017B |
| October 28, 2024 | 1.035B |
| October 25, 2024 | 995.45M |
| October 24, 2024 | 1.002B |
| October 23, 2024 | 985.72M |
| October 22, 2024 | 1.012B |
| October 21, 2024 | 1.063B |
| October 18, 2024 | 1.018B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.007B |
| October 16, 2024 | 1.008B |
| October 15, 2024 | 1.010B |
| October 14, 2024 | 999.23M |
| October 11, 2024 | 985.72M |
| October 10, 2024 | 969.50M |
| October 09, 2024 | 995.45M |
| October 08, 2024 | 1.011B |
| October 07, 2024 | 1.010B |
| October 04, 2024 | 1.018B |
| October 03, 2024 | 995.99M |
| October 02, 2024 | 1.010B |
| October 01, 2024 | 970.58M |
| September 30, 2024 | 964.10M |
| September 27, 2024 | 1.189B |
| September 26, 2024 | 1.178B |
| September 25, 2024 | 1.107B |
| September 24, 2024 | 1.116B |
| September 23, 2024 | 1.113B |
| September 20, 2024 | 1.139B |
| September 19, 2024 | 1.162B |
| September 18, 2024 | 1.158B |
| September 17, 2024 | 1.156B |
| September 16, 2024 | 1.176B |
| September 13, 2024 | 1.209B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
826.80M
Minimum
Feb 07 2024
7.660B
Maximum
Aug 13 2020
2.685B
Average
2.072B
Median
Jul 11 2022
Enterprise Value Benchmarks
| Geovax Labs Inc | 16.88M |
| Tonix Pharmaceuticals Holding Corp | 17.92M |
| Abbott Laboratories | 210.81B |
| Insulet Corp | 18.87B |
| SIGA Technologies Inc | 348.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 114.80M |
| Revenue (Quarterly) | 283.80M |
| Total Expenses (Quarterly) | 219.30M |
| EPS Diluted (Quarterly) | 2.06 |
| Gross Profit Margin (Quarterly) | 56.80% |
| Profit Margin (Quarterly) | 40.45% |
| Earnings Yield | -43.11% |
| Normalized Earnings Yield | -42.30 |